The effect of dexamethasone on sudden sensorineural hearing loss

Evaluation of dexamethasone injection in the middle ear cavity for the treatment of sudden sensorineural hearing loss and comparison with standard methods

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211010052721N1

Enrollment

120

Registered

2021-10-25

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden sensorineural hearing loss. Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side

Interventions

Intervention 1: First Intervention group: In this group, 40 patients with sudden sensorineural hearing loss (SSNHL) in addition to routine treatment, would take middle ear cavity injection of dexameth

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with sudden sensorineural hearing loss lasting from 72 hours to less than 30 days after the onset of symptoms Conscious consent to participate in the study

Exclusion criteria

Exclusion criteria: Consumption other medications in addition to prescribed medicationsPregnancy Allergy to prescription drugs Known genetic neurosensory deafness or known anomaly of the inner ear Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Average hearing threshold. Timepoint: Mean hearing threshold before study and 10 and 12 days after using dexamethasone. Method of measurement: Audiometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Nourizadeh

Mashhad University of Medical Sciences

nourizadehn@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026